Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Atara Biotherapeutics Inc    ATRA

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Insider Trading Activity Atara Biotherapeutics Inc (NASDAQ:ATRA) – CEO Sold 30,800 shares of Stock

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/21/2017 | 01:20am CET

Insider Trading Activity For Atara Biotherapeutics Inc (NASDAQ:ATRA)

Isaac E Ciechanover , CEO of Atara Biotherapeutics Inc (NASDAQ:ATRA) reportedly Sold 30,800 shares of the company’s stock at an average price of 19.38 for a total transaction amount of $596,904.00 SEC Form

Insider Trading History For Atara Biotherapeutics Inc (NASDAQ:ATRA)

  • On 10/21/2014Domain Partners Viii, L.P., Major Shareholder, bought 248,159 with an average share price of $11.00 per share and the total transaction amounting to $2,729,749.00. View SEC Filing
  • On 2/18/2015Carol Giltner Gallagher, Director, bought 11,000 with an average share price of $18.00 per share and the total transaction amounting to $198,000.00. View SEC Filing
  • On 3/10/2015 Joel S Marcus, Director, bought 4,000 with an average share price of $29.57 per share and the total transaction amounting to $118,280.00. View SEC Filing
  • On 4/23/2015 Isaac E Ciechanover, CEO, sold 5,200 with an average share price of $61.36 per share and the total transaction amounting to $319,072.00. View SEC Filing
  • On 5/22/2015 Isaac E Ciechanover, CEO, sold 4,000 with an average share price of $37.56 per share and the total transaction amounting to $150,240.00. View SEC Filing
  • On 5/29/2015John Mcgrath, CFO, sold 10,000 with an average share price of $40.00 per share and the total transaction amounting to $400,000.00. View SEC Filing
  • On 6/1/2015Christopher Haqq, Insider, sold 2,500 with an average share price of $41.47 per share and the total transaction amounting to $103,675.00. View SEC Filing
  • Analyst Ratings For Atara Biotherapeutics Inc (NASDAQ:ATRA)
    These are 2 Sell Ratings, 3 Buy Ratings .
    The current consensus rating for Atara Biotherapeutics Inc (NASDAQ:ATRA) is Hold (Score: 2.20) with a consensus target price of $24.00 , a potential (12.94% upside)

    Analyst Ratings History For Atara Biotherapeutics Inc (NASDAQ:ATRA)

    • On 12/15/2015 William Blair Reiterated Rating Buy
    • On 3/9/2016 JPMorgan Chase & Co. Lower Price Target of rating Market Outperform with a price target of $40.00 to $34.00
    • On 7/9/2016 JMP Securities Reiterated Rating Buy
    • On 9/15/2016 Goldman Sachs Group Inc Downgraded rating Neutral to Sell with a price target of $23.00 to $16.00
    • On 12/12/2016 Jefferies Group LLC Set Price Target of rating Buy with a price target of $23.00
    • On 3/11/2017 Canaccord Genuity Set Price Target of rating Buy with a price target of $47.00
    • On 3/16/2017 Citigroup Inc Set Price Target of rating Sell with a price target of $10.00

    About Atara Biotherapeutics Inc (NASDAQ:ATRA)
    Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. Its T-cell product candidates include Epstein Barr Virus-cytotoxic T lymphocytes (EBV-CTL), which is in Phase II clinical trials for malignancies associated with EBV; cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1. Its molecularly targeted product candidates include STM 434, which is in Phase I clinical trial of STM 434 for ovarian cancer and other solid tumors; ATA 777, a fully human antibody targeting Activin A; ATA M43, a fully human anti-Actin-related protein 2-A (ActR2A)/2B monoclonal antibody; STM 217; ActR2B5, and ATA 842, a humanized antibody targeting myostatin.

    Recent Trading Activity for Atara Biotherapeutics Inc (NASDAQ:ATRA)
    Shares of Atara Biotherapeutics Inc closed the previous trading session at 21.25 up +1.20 5.99% with 374,681 shares trading hands.

    The post Insider Trading Activity Atara Biotherapeutics Inc (NASDAQ:ATRA) – CEO Sold 30,800 shares of Stock appeared first on Market Exclusive.

    © Market Exclusive 2017, source Market Exclusive

    share with twitter share with LinkedIn share with facebook
    share via e-mail
    0
    Latest news on ATARA BIOTHERAPEUTICS INC
    01/10 ATARA BIOTHERAPEUTICS : Announces FDA Clearance to Proceed with Enrollment at U...
    01/05 ATARA BIOTHERAPEUTICS : Starts Two Phase 3 Trials of Treatment for Lymphoma That..
    01/05 ATARA BIOTHERAPEUTICS : BioCentury - Atara prices $127.8M follow-on
    01/05 ATARA BIOTHERAPEUTICS, INC. (NASDAQ : ATRA) Files An 8-K Other Events
    01/04 ATARA BIOTHERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (f..
    01/04 Atara Biotherapeutics to Present at the 36th Annual J.P. Morgan Healthcare Co..
    01/04 ATARA BIOTHERAPEUTICS : Announces Pricing of Public Offering of Common Stock
    01/04 Atara Biotherapeutics Announces Pricing of Public Offering of Common Stock
    01/03 ATARA BIOTHERAPEUTICS : Announces Proposed Offering of Common Stock
    01/03 ATARA BIOTHERAPEUTICS : Announces Initiation of Two Phase 3 Clinical Studies to ..
    More news
    News from SeekingAlpha
    01/14 APLS - Addendum, How A Company Tries To Make Lemonade Out Of Lemons
    01/12 Atara Bio builds on ATA188-stoked up move, shares ahead 35%
    01/12 Midday Gainers / Losers (1/12/2018)
    01/12 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (1/12/2018)
    01/12 ATARA BIOTHERAPEUTICS : What The FDA Clearance For ATA-188 Phase 1 Study At US S..
    Financials ($)
    Sales 2017 -
    EBIT 2017 -122 M
    Net income 2017 -119 M
    Finance 2017 60,2 M
    Yield 2017 -
    P/E ratio 2017 -
    P/E ratio 2018
    EV / Sales 2017 0
    EV / Sales 2018 638x
    Capitalization 864 M
    Chart ATARA BIOTHERAPEUTICS INC
    Duration : Period :
    Atara Biotherapeutics Inc Technical Analysis Chart | ATRA | US0465131078 | 4-Traders
    Technical analysis trends ATARA BIOTHERAPEUTICS INC
    Short TermMid-TermLong Term
    TrendsBullishBullishBullish
    Income Statement Evolution
    Consensus
    Sell
    Buy
    Mean consensus OUTPERFORM
    Number of Analysts 6
    Average target price 29,6 $
    Spread / Average Target 4,8%
    EPS Revisions
    Managers
    NameTitle
    Issac E. Ciechanover Chairman, President & Chief Executive Officer
    John F. McGrath Chief Financial Officer & Executive Vice President
    Christopher M. Haqq Chief Scientific Officer, Executive VP-R&D
    Joe Newell Chief Technical Operations Officer & Executive VP
    Kanya Rajangam Chief Medical Officer & Senior Vice President
    Sector and Competitors
    1st jan.Capitalization (M$)
    ATARA BIOTHERAPEUTICS INC52.21%843
    GILEAD SCIENCES12.02%104 801
    REGENERON PHARMACEUTICALS-1.53%39 775
    VERTEX PHARMACEUTICALS3.90%39 380
    GENMAB12.29%11 532
    EXELIXIS, INC.-2.47%8 772